Ropes & Gray advised Acumen Pharmaceuticals in a global non-exclusive collaboration and license agreement with Halozyme Therapeutics. Acumen will explore the potential use of ENHANZE subcutaneous drug delivery technology with Acumen’s clinical stage monoclonal antibody to target amyloid beta oligomers for the treatment of early Alzheimer’s disease. The transaction was announced on November 6.
Under the agreement, in return for an upfront payment to Halozyme and other considerations, Acumen will receive non-exclusive rights to ENHANZE. Acumen is obligated to make future payments to Halozyme, subject to achievement of specified development, regulatory and sales milestones. Halozyme will also be entitled to receive royalties on sales of commercialized medicines using the ENHANZE delivery technology.
The Ropes & Gray team included life sciences transactions partner Hannah England and intellectual property transactions associate Parker Elliot.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.From Legal Desire
Is your firm the one being cited, or the one being skipped?
We ran the test. On several everyday legal questions, software companies are answering and law firms are not. We help firms fix that, and we build the technology behind the practice.
Lawyers and firms: get featured on Legal Desire
Share your deals, lateral moves, firm news and insights with 1M+ monthly readers: founders, law firm partners, general counsel and practising lawyers across the US, UK, EU and GCC.
Get featuredSubmit a press releaseThe advising firms, the named deal team, the value and the parties, with every other announced deal by the same firms and lawyers. Open the deal record
